Abstract 107P
Background
Although complete resection of colorectal cancer liver metastasis (CLM) is the only potentially curative treatment, surgery alone is not enough, as the recurrence rate after resection of CLM is high. Therefore, in clinical practice, adjuvant chemotherapy (AC) has been performed after resection of CLM. However, the evidence supporting the efficacy of AC after resection of CLM is not sufficient. Previous reports have noted that AC after resection of CLM is effective only in patients with a high risk of recurrence. The purpose of this study was to classify the risk of recurrence using systemic inflammatory markers, which have been reported to be associated with the clinical outcomes, and to evaluate the efficacy of AC according to the risk of recurrence.
Methods
We retrospectively reviewed the medical records of 119 patients with CLM who underwent potentially curative surgery. The C-reactive protein-to-albumin ratio (CAR) was calculated from the blood samples by dividing the serum C-reactive protein level by the serum albumin level. The optimal cut-off value of the CAR was determined according to the ROC curve analysis, and then the patients were classified into the high- or low-CAR group. We examined the relationship between the CAR and the relapse-free survival (RFS) after resection of CLM and evaluated the efficacy of AC according to the risk of recurrence.
Results
The cut-off value of the CAR was set at 0.0471 based on the ROC curve analysis. The RFS rates were significantly better in the low-CAR group than in the high-CAR group. The efficacy of AC after resection of CLM was not recognized in the low-CAR group (with a low risk of recurrence), whereas the RFS rates were significantly better for the patients who were treated with AC after resection of CLM in the high-CAR group (with a high risk of recurrence).
Conclusions
The preoperative CAR was found to be useful as prognostic markers in patients with CLM who were treated with potentially curative resection. Furthermore, it was suggested that AC after resection of CLM may be effective for preventing recurrence in patients with high inflammatory markers who have a high risk of recurrence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Osaka City University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract